For Healthcare Professionals For Patients and Caregivers Important Safety Information Medication Guide ACTIMMUNE.com
PATIENT RESOURCES

Resources to Support Your Patients Throughout Their Treatment Experience

Discover helpful resources to share with your office, patient, or their caregivers. These digital resources can help them get started or learn more about the support available while on ACTIMMUNE® (Interferon gamma-1b).

PAL-IconPAL-Icon

Clinical Nurse Educator

The Clinical Nurse Educator (CNE) is a dedicated support partner who helps investigate, explain, and educate on each step of the treatment experience. They are your patient’s point of contact and constant champion in helping accomplish their treatment goals. Learn more about contacting a CNE and why your patient should connect with one.
Hear what an Amgen CNE has to say about how she helps patients
Watch Video
Read Transcript

Carol: When I'm going to be meeting with a patient and their family, explaining what my role is. I want them to understand that I will be a point person for them first, and foremost, I'm there to listen to what their story is, and then also let them know that I will be there to support them and ultimately to empower them.

I look at my role as being able to take as much off their plate as I can as they navigate that process, but also helping them understand in layman's terms where they are in the process and what they need to do on their end. We don't want patients to feel that they're just out there alone and floating in the space of the unknown.

We want patients to know they can reach out to us at any time or family member or caregiver. We're always available to them. This company is definitely a company that puts patients first.

Injection Education Guide

Use this tool to provide injection reminders and show patients how to measure the dose, choose the injection site, and store ACTIMMUNE.

Injection Tracking Download

Helps your patient track the days and sites of their ACTIMMUNE injections.

Managing Side Effects

Tips to manage certain side effects for your patient.

CGD Facts

Learn more about CGD and get the facts.

Patient Advocacy Organizations for Those Living With Chronic Granulomatous Disease (CGD)

Please note the below is not comprehensive, and Amgen does not confirm accuracy or otherwise endorse any of these organizations.

  • CGD Association of America

    CGD Association of America is an independent, nonprofit organization that is committed to advocating for patients and carriers with CGD.

    cgdaa.org

  • Immune Deficiency Foundation

    The Immune Deficiency Foundation (IDF) is a national nonprofit patient organization dedicated to improving the lives of people with different kinds of primary immunodeficiency diseases, such as CGD. IDF provides a wide variety of resources for people with CGD, including information about diagnosis and treatment options.

    primaryimmune.org

  • Jeffrey Modell Foundation

    The Jeffrey Modell Foundation is a nonprofit organization devoted to diagnosis, meaningful treatments, and cures for primary immunodeficiency diseases. Thirty years after its creation, the organization continues its mission of hope, advocacy, and action by supporting the medical and global patient community.

    info4pi.org

  • Remember the Girls

    The mission of Remember the Girls is to raise awareness of the many issues facing female carriers of X-linked genetic disorders; to provide a forum for X-linked females to share their stories, ask questions, provide and receive emotional support; and to advocate for increased attention of the medical community to the physical and emotional issues of females who carry X-linked disorders.

    rememberthegirls.org

Patient Advocacy Organizations for Those Living With a Rare Disease

Please note the below is not comprehensive, and Amgen does not confirm accuracy or otherwise endorse any of these organizations.

  • Global Genes

    Global Genes is a nonprofit organization for patients and families fighting rare and genetic diseases like CGD. Their mission is to provide connections and resources so people can become activists for their disease and feel empowered to keep moving forward.

    globalgenes.org
  • National Organization for Rare Disorders (NORD)

    NORD is a patient advocacy organization dedicated to people with rare diseases and the groups that help them. NORD provides patients and families with advocacy information, assistance programs, and connections to patient organizations.

    rarediseases.org

  • EveryLife Foundation for Rare Diseases

    The EveryLife Foundation for Rare Diseases is dedicated to accelerating biotech innovation for rare disease treatments through science-driven public policy.

    EveryLifeFoundation.org

  • Rare Givers

    Rare Givers connects rare communities to teach the tools of self-care and how to be listened to without judgment.

    raregivers.global

  • Our Odyssey

    Our Odyssey’s mission is connecting young adults impacted by a rare or chronic condition with social and emotional support in the hope of improving their quality of life.

    ourodyssey.org

  • Next Step

    Next Step is a non-profit that shatters limitations and elevates aspirations of young people with serious illness during their transition to adulthood through campferences, mentorship, music therapy, and other tailored programming.

    nextstepnet.org

  • Mejo

    Online digital tool that helps to keep track of patient medical and care information (free to use, additional features that can be paid for)

    mymejo.com

Once you decide ACTIMMUNE is right for your patient, you can initiate their enrollment in Amgen By Your Side

Familiarize yourself with important forms and downloadable resources that explain the process

You are leaving AmgenByYourSide.com

You are leaving AmgenByYourSide.com. You will be redirected to a website operated by an independent third party. This link is provided solely for your convenience.
Continue Cancel

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with chronic granulomatous disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis

Important Safety Information

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli-derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Before starting ACTIMMUNE and every 3 months during treatment, hematologic tests, blood chemistries, and urinalysis are recommended for all patients
    • Patients begun on ACTIMMUNE before the age of 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE

    • USE IN SPECIFIC POPULATIONS:

    • ACTIMMUNE should be used during pregnancy only if the potential benefit to the patient outweighs the potential risk to the fetus
    • It is not known if ACTIMMUNE is excreted in human milk, so either ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the patient
    • In younger patients, long-term effects of ACTIMMUNE on fertility are not known
    • In animal studies, both male and female fertility was negatively impacted by doses significantly higher than the maximum clinical dose

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness
Please see accompanying Full Prescribing Information for complete safety information.

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with chronic granulomatous disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis

Important Safety Information

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli-derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Before starting ACTIMMUNE and every 3 months during treatment, hematologic tests, blood chemistries, and urinalysis are recommended for all patients
    • Patients begun on ACTIMMUNE before the age of 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE

    • USE IN SPECIFIC POPULATIONS:

    • ACTIMMUNE should be used during pregnancy only if the potential benefit to the patient outweighs the potential risk to the fetus
    • It is not known if ACTIMMUNE is excreted in human milk, so either ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the patient
    • In younger patients, long-term effects of ACTIMMUNE on fertility are not known
    • In animal studies, both male and female fertility was negatively impacted by doses significantly higher than the maximum clinical dose

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness
Please see accompanying Full Prescribing Information for complete safety information.